245 related articles for article (PubMed ID: 33300159)
21. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
Son HW; Yokota T
Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
[TBL] [Abstract][Full Text] [Related]
22. Targeting SR proteins improves SMN expression in spinal muscular atrophy cells.
Wee CD; Havens MA; Jodelka FM; Hastings ML
PLoS One; 2014; 9(12):e115205. PubMed ID: 25506695
[TBL] [Abstract][Full Text] [Related]
23. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy.
Kashima T; Manley JL
Nat Genet; 2003 Aug; 34(4):460-3. PubMed ID: 12833158
[TBL] [Abstract][Full Text] [Related]
24. ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy.
Ottesen EW
Transl Neurosci; 2017 Jan; 8():1-6. PubMed ID: 28400976
[TBL] [Abstract][Full Text] [Related]
25. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.
Singh NN; Howell MD; Androphy EJ; Singh RN
Gene Ther; 2017 Sep; 24(9):520-526. PubMed ID: 28485722
[TBL] [Abstract][Full Text] [Related]
26. SRSF10: an atypical splicing regulator with critical roles in stress response, organ development, and viral replication.
Shkreta L; Delannoy A; Salvetti A; Chabot B
RNA; 2021 Nov; 27(11):1302-1317. PubMed ID: 34315816
[TBL] [Abstract][Full Text] [Related]
27. Pre-mRNA Splicing Modulation by Antisense Oligonucleotides.
Singh NN; Luo D; Singh RN
Methods Mol Biol; 2018; 1828():415-437. PubMed ID: 30171557
[TBL] [Abstract][Full Text] [Related]
28. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
Singh NN; Lee BM; DiDonato CJ; Singh RN
Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
[TBL] [Abstract][Full Text] [Related]
29. A splicing silencer in SMN2 intron 6 is critical in spinal muscular atrophy.
Wang L; Ji Y; Chen Y; Bai J; Gao P; Feng P
Hum Mol Genet; 2023 Mar; 32(6):971-983. PubMed ID: 36255739
[TBL] [Abstract][Full Text] [Related]
30. Oxidative Stress Triggers Body-Wide Skipping of Multiple Exons of the Spinal Muscular Atrophy Gene.
Seo J; Singh NN; Ottesen EW; Sivanesan S; Shishimorova M; Singh RN
PLoS One; 2016; 11(4):e0154390. PubMed ID: 27111068
[TBL] [Abstract][Full Text] [Related]
31. Splicing-Correcting Therapy for SMA.
Wan L; Dreyfuss G
Cell; 2017 Jun; 170(1):5. PubMed ID: 28666123
[TBL] [Abstract][Full Text] [Related]
32. Structure and function analysis of Sam68 and hnRNP A1 synergy in the exclusion of exon 7 from SMN2 transcripts.
Nadal M; Anton R; Dorca-Arévalo J; Estébanez-Perpiñá E; Tizzano EF; Fuentes-Prior P
Protein Sci; 2023 Apr; 32(4):e4553. PubMed ID: 36560896
[TBL] [Abstract][Full Text] [Related]
33. HnRNP C1/C2 may regulate exon 7 splicing in the spinal muscular atrophy gene SMN1.
Irimura S; Kitamura K; Kato N; Saiki K; Takeuchi A; Gunadi ; Matsuo M; Nishio H; Lee MJ
Kobe J Med Sci; 2009 Mar; 54(5):E227-36. PubMed ID: 19628962
[TBL] [Abstract][Full Text] [Related]
34. A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy.
Singh NN; Shishimorova M; Cao LC; Gangwani L; Singh RN
RNA Biol; 2009; 6(3):341-50. PubMed ID: 19430205
[TBL] [Abstract][Full Text] [Related]
35. RNA in spinal muscular atrophy: therapeutic implications of targeting.
Singh RN; Seo J; Singh NN
Expert Opin Ther Targets; 2020 Aug; 24(8):731-743. PubMed ID: 32538213
[TBL] [Abstract][Full Text] [Related]
36. CASH: a constructing comprehensive splice site method for detecting alternative splicing events.
Wu W; Zong J; Wei N; Cheng J; Zhou X; Cheng Y; Chen D; Guo Q; Zhang B; Feng Y
Brief Bioinform; 2018 Sep; 19(5):905-917. PubMed ID: 28387786
[TBL] [Abstract][Full Text] [Related]
37. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy.
Mitrpant C; Porensky P; Zhou H; Price L; Muntoni F; Fletcher S; Wilton SD; Burghes AH
PLoS One; 2013; 8(4):e62114. PubMed ID: 23630626
[TBL] [Abstract][Full Text] [Related]
38. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.
Porensky PN; Mitrpant C; McGovern VL; Bevan AK; Foust KD; Kaspar BK; Wilton SD; Burghes AH
Hum Mol Genet; 2012 Apr; 21(7):1625-38. PubMed ID: 22186025
[TBL] [Abstract][Full Text] [Related]
39. A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophy.
Vezain M; Saugier-Veber P; Goina E; Touraine R; Manel V; Toutain A; Fehrenbach S; Frébourg T; Pagani F; Tosi M; Martins A
Hum Mutat; 2010 Jan; 31(1):E1110-25. PubMed ID: 19953646
[TBL] [Abstract][Full Text] [Related]
40. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2).
Hofmann Y; Lorson CL; Stamm S; Androphy EJ; Wirth B
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9618-23. PubMed ID: 10931943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
